Sort   by:  
 Page size 
UnknownSticky nanoparticles: a platform for siRNA delivery by a bis(zinc(II) dipicolylamine)-functionalized, self-assembled nanoconjugate.
Not available
S-EPMC3622591 | biostudies-literature
UnknownImmunochip analysis identification of 6 additional susceptibility loci for Crohn's disease in Koreans.
Not available
S-EPMC4331109 | biostudies-literature
ProteomicsA CLIC1 network coordinates matrix stiffness and the Warburg effect to promote tumor growth in pancreatic cancer
The proteomics cohort with PET-CT information (n = 8) were divided into two groups according to the SUV-max, and gene expression in these two groups of PDAC tissues was screened for glucose metabolism-correlated DEGs
ORGANISM(S): Homo Sapiens 
PXD053962 |
UnknownReplication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium.
Not available
S-EPMC2897877 | biostudies-literature
UnknownGenotypic variants at 2q33 and risk of esophageal squamous cell carcinoma in China: a meta-analysis of genome-wide association studies.
Not available
S-EPMC3315211 | biostudies-literature
UnknownGenome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia.
Not available
S-EPMC4169232 | biostudies-literature
UnknownMeta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women.
Not available
S-EPMC4731021 | biostudies-literature
UnknownGenetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia.
Not available
S-EPMC4733320 | biostudies-literature
UnknownIdentification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk.
Not available
S-EPMC6089967 | biostudies-literature
UnknownDurvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Not available
S-EPMC10824389 | biostudies-literature
Sort   by:  
 Page size